Figure 7.
Long-acting acylated-OXT and acylated-OXTGly promote weight loss and lipid metabolism in vivo. Twenty-week-old C57BL/6 DIO mice (n = 7 per group) were dosed daily with OXT analogs (2 μmol/kg, SC) for 2 wk. (A) Cumulative body weight change. (B) Cumulative food consumption. (C) Fat and lean mass were measured by quantitative nuclear magnetic resonance at the beginning and end of study. (D–F) Plasma low-density lipoprotein (LDL) cholesterol (D), liver triglyceride (E), and plasma free fatty acid (F) were measured at the end of the study. (G) Liver gene expression changes. (H and I) ipGTTs were conducted at the end of the study. (J and K) Fasting plasma glucose (J) and insulin (K) were also measured at the end of study. Two-way ANOVA followed by a Dunnett multiple comparisons test were used for (A), (B), and (H). One-way ANOVA followed by a Dunnett multiple comparisons test were used for panels (C)–(G) and (I)–(K). For all statistical analyses: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.